At 0.5x sales and 13.8x forward earnings, the market is clearly pricing AMBP as a low-growth, balance-sheet-constrained cyclical rather than a compounder. The 1.1 Altman Z-Score is deep in distress territory, and a 4.40 Debt/Equity ratio confirms the balance sheet is aggressively levered, which explains the discounted multiple. Yet the absence of a trailing P/E and a forward multiple that is not demanding suggests investors are betting on stabilization rather than growth. This is not a premium story; it is a leveraged value stub where survival and modest execution could justify upside, but financial fragility caps enthusiasm.